01/03/2026
Selvom jeg gennem årene, har klienter, der rapporterer netop dette, så er artiklen desværre ikke baseret på reel videnskab.
Men fint AI billede er det da 👍🐸🤗
Pharmacologists at the Federal University of São Paulo, studying the skin secretions of the giant monkey frog (Phyllomedusa bicolor) — used for centuries by Amazonian Matses hunters in traditional ritual practices — have isolated and characterized a neuropeptide called Dermorphin-B7 that blocks pain signaling through a novel receptor not previously identified in human pain biology. In clinical trials with chronic pain patients unresponsive to opioids, NSAIDs, and nerve blocks, a single subcutaneous injection of synthetic Dermorphin-B7 provided complete pain relief for an average of 47 days — with zero opioid receptor activity, zero addiction potential, and zero tolerance development. The jungle pharmacopoeia just produced pain medicine's most significant finding in decades. 🐸
Standard pain management operates almost entirely through opioid receptors (morphine, oxycodone), cyclooxygenase inhibition (ibuprofen, aspirin), or sodium channel blockade (lidocaine). All three pathways have fundamental limitations: opioids produce addiction and tolerance, COX inhibitors carry cardiovascular and GI risks with long-term use, and sodium channel blockers can't be delivered systemically without cardiac toxicity. Dermorphin-B7 acts on a newly characterized nociceptor receptor — GPR-34 variant — that modulates C-fiber pain transmission without touching any of these existing pathways. It's a fourth route into pain biology that pharmacology didn't know existed.
Chronic pain affects 50 million Americans and costs $635 billion annually in treatment and lost productivity. The opioid epidemic — which killed 80,000 Americans in 2023 — was partly a consequence of the absence of non-addictive alternatives for severe chronic pain. A peptide that provides month-long complete pain relief without addiction potential would be the most important development in pain pharmacology since the discovery of morphine itself.
UNIFESP has licensed Dermorphin-B7 synthesis to two US pharmaceutical companies for Phase II trials. The frog that Amazonian tribes have revered for their pain-relieving properties may have been holding the future of medicine all along.
Source: Federal University of São Paulo / UNIFESP, Nature Chemical Biology 2025
